Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data.
It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.
The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has commenced trading.
Stocks highlighted in yellow have made market-moving announcements (click headings to sort).
| Code | Name | Last | % | Volume |
|---|---|---|---|---|
| CGB | Cann Global Limited | 0.005 | 25 | 2530198 |
| IXR | Ionic Rare Earths | 0.016 | 23 | 22209301 |
| LSH | Lifespot Health Ltd | 0.06 | 22 | 1722345 |
| PPY | Papyrus Australia | 0.017 | 21 | 848392 |
| RAN | Range International | 0.017 | 21 | 1583075 |
| RWD | Reward Minerals Ltd | 0.17 | 21 | 328021 |
| MLS | Metals Australia | 0.003 | 20 | 418333 |
| MNB | Minbos Resources Ltd | 0.003 | 20 | 3000000 |
| ICU | Isentric Ltd. | 0.11 | 20 | 4442689 |
| EMT | Emetals Limited | 0.021 | 17 | 2396793 |
Potash stock Reward Minerals (ASX:RWD) obtained commonwealth environmental approval for its Lake Disappointment Potash project.
Lifespot Health (ASX:LSH) and Papyrus (ASX:PPY) both rose with news of capital raisings. Lifespot’s announcement was accompanied by a sales update.
| Code | Name | Last | % | Volume |
|---|---|---|---|---|
| CML | Chase Mining Limited | 0.016 | -50 | 10518970 |
| MSB | Mesoblast Limited | 3.08 | -39 | 12019062 |
| ANW | Aus Tin Mining | 0.001 | -33 | 5636362 |
| ECT | Env Clean Tech Ltd. | 0.001 | -33 | 610000 |
| PSL | Paterson Resources | 0.003 | -25 | 500000 |
| NWM | Norwest Minerals | 0.12 | -23 | 136172 |
| CZL | Cons Zinc Ltd | 0.004 | -20 | 149999 |
| CZN | Corazon Ltd | 0.002 | -20 | 1882333 |
| BUX | Buxton Resources Ltd | 0.075 | -17 | 192585 |
| BSM | Bass Metals Ltd | 0.003 | -14 | 3857500 |
Gold play Chase Mining (ASX:CML) fell after exploration results that left even the company disappointed.
Biotech Mesoblast (ASX:MSB) also dropped after being ordered by the FDA to conduct another clinical trial.